Horizon Pharma Targets Actavis Over Generic Rayos

Law360, New York (August 28, 2013, 6:52 PM EDT) -- Swiss drugmakers Horizon Pharma AG and Jagotec AG hit Actavis Inc. with a suit in New Jersey federal court Monday, sayings its planned generic version of anti-inflammatory drug Rayos infringes several patents covering the drug and its dispenser.

According to Horizon, a planned generic version of delayed-release prednisone tablets by Actavis and Watson infringes five patents licensed by Horizon and Jagotec for Rayos — U.S. Patent Numbers 6,488,960; 6,677,326; 8,168,218; 8,309,124; and 8,394,407.

“Plaintiffs will be substantially and irreparably harmed if defendants are not enjoined from...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.